Project Grant R01HL174789
Award Date
8/1/24
Completion Date
7/31/28
Dollars Obligated
$657K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This federal Project Grant award of $128,877, provided by the National Heart Lung and Blood Institute under CFDA 93.837 Cardiovascular Diseases Research, supports research to elucidate the mechanisms necessary for curing myelodysplastic syndromes (MDS). The key objectives are to: (1) assess the potential for detecting MDS hematopoietic stem cells to predict relapse after allogeneic stem cell transplant, and (2) investigate the molecular and clonal evolution of MDS stem cells that enables their...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $161,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Albert Einstein College of Medicine. The grant, awarded on July 9, 2025, will fund research to elucidate the interplay between DDX41 and CUX1 mutations and their impact on hematopoiesis in zebrafish and human induced pluripotent stem cells. The project aims to provide mechanistic insights into how these co-occurring mutations contribute to the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $435,804 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant will fund research to elucidate the mechanistic basis for the selective advantage of the acquired DDX41R525H mutation in hematopoietic stem cells (HSCs) of patients with germline DDX41 mutations, who develop myelodysplastic syndrome (MDS) and related myeloid malignancies. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,387 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Colorado-Denver. The grant, with a project period from January 1, 2025 to December 31, 2029, aims to investigate the role of miR-301B in regulating autophagy and its impact on cardiac function in pediatric dilated cardiomyopathy (DCM). The key objectives are to: 1) Determine the expression levels of autophagy-related proteins...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $121,875 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, for the project "A MAP OF RIBOSOMAL RNA REGULATION IN HUMAN HEMATOPOIESIS". This 2-year grant (award date: Sep 1, 2024, completion date: Aug 31, 2026) will support research to quantify dynamics of ribosomal DNA (rDNA) activation...
This federal Project Grant award for $1,088,500.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports three independent research projects at The University of Iowa focused on genetic and molecular mechanisms of heart disease. The first project aims to define microRNA targeting events and their biological relevance in the heart, as well as understand the clinical significance of genetic variants that alter...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $773,257 to St. Jude Children's Research Hospital Inc. to investigate the mechanisms of lysosome segregation and cell fate regulation in dividing hematopoietic stem cells (HSCs). The research aims to identify factors regulating lysosome segregation during HSC division and how this process influences HSC self-renewal and...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $146,922 to the Albert Einstein College of Medicine to investigate the mechanisms driving hematopoietic stem and progenitor cell (HSPC) dysfunction associated with the inherited form of myelodysplastic syndrome (MDS). The research aims to decipher how environmental factors synergize with the DDX41 gene mutation to promote HSPC dysfunction, including the potential...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $169,156 to The Washington University in St. Louis to support a 5-year research program focused on optimizing hematopoietic stem cell transplantation (HSCT) to treat non-malignant diseases, particularly sickle cell disease (SCD). The key objectives are to: 1) Evaluate novel stem cell mobilization regimens combining VLA-4 and CXCR4 inhibition to generate...
This Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) aims to uncover novel regulatory pathways and functions of the telomerase RNA component (TERC) in the hematopoietic system. The $623,874 award, effective December 15, 2024 through November 30, 2028, will support research at Washington University in St. Louis to: Determine the role of novel 3'-end RNA deadenylases in TERC processing and decay in blood cells,...